文献速递口腔黏膜病

COVID-19患者的口腔表现:一项动态系统综述

Oral Manifestations in Patients with COVID-19: A Living Systematic Review.
PubMed 文献 · J Dent Res · 2020-09-11

该动态系统综述旨在总结COVID-19患者口腔体征和症状的患病率证据。检索6个数据库及灰色文献后纳入40项研究(33项横断面研究、7项病例报告),共评估来自19个国家的10,228例患者。味觉障碍是最常见的口腔表现,患病率为45%(95%CI 34%至55%;I2=99%),且味觉障碍与COVID-19、轻/中度严重程度及女性患者相关。口腔黏膜病变临床表现多样,在轻症患者中可先于或与初始呼吸道症状同时出现,在需用药和住院的患者中约在症状出现后7至24天发生。

要点

  • 味觉障碍是COVID-19常见口腔表现,汇总患病率45%。
  • 味觉障碍与COVID-19显著相关(OR=12.68)。
  • 口腔黏膜病变表现多样,可为共感染或继发表现。

核心结论

  • 味觉障碍可能是COVID-19患者的常见症状,应在疾病起病和进展范围内予以考虑。
  • 口腔黏膜病变更可能表现为共感染和继发表现,具有多种临床形态。

研究设计与样本

  • 动态系统综述,按PRISMA清单报告,检索6个数据库和灰色文献。
  • 纳入提及COVID-19患者口腔症状和体征的任何语言研究,最终纳入40项研究:33项横断面研究和7项病例报告。
  • 共评估来自19个国家的10,228例患者(4,288例男性、5,770例女性、170例性别未知)。
  • 偏倚风险采用Joanna Briggs Institute评估工具,证据确定性通过GRADE评估。

主要发现

  • 味觉障碍是最常见的口腔表现,患病率为45%(95%CI 34%至55%;I2=99%)。
  • 不同味觉障碍的汇总 eligible 数据:味觉倒错为38%,味觉减退为35%,味觉丧失患病率为24%。
  • 味觉障碍与COVID-19相关(OR=12.68;95%CI 6.41至25.10;I2=63%;P<0.00001)。
  • 味觉障碍与轻/中度严重程度相关(OR=2.09;95%CI 1.25至3.49;I2=66%;P=0.005)。
  • 味觉障碍与女性患者相关(OR=1.64;95%CI 1.23至2.17;I2=70%;P=0.0007)。

关键数值与推荐

  • 口腔黏膜病变临床表现包括白色和红斑性斑块、不规则溃疡、小水疱、瘀点及剥脱性龈炎。
  • 受累部位包括舌、腭、唇、牙龈和颊黏膜。
  • 在轻症病例中,口腔黏膜病变先于或与初始呼吸道症状同时出现;在需用药和住院的患者中,病变约在症状出现后7至24天发生。

临床怎么用

  • 在COVID-19的起病和进展评估中,应将味觉障碍视为常见症状加以考虑。
  • 对口腔黏膜病变应认识其多种临床形态,并考虑其作为共感染或继发表现的可能。

局限性

  • 味觉障碍患病率汇总存在高度异质性(I2=99%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This living systematic review aims to summarize evidence on the prevalence of oral signs and symptoms in patients with COVID-19. The review was reported per the PRISMA checklist, and the literature search was conducted in 6 databases and in gray literature. Studies published in any language mentioning oral symptoms and signs in patients with COVID-19 were included. The risk of bias was assessed by the Joanna Briggs Institute appraisal tools. The certainty of evidence was evaluated through GRADE assessment. After a 2-step selection, 40 studies were included: 33 cross-sectional and 7 case reports. Overall, 10,228 patients (4,288 males, 5,770 females, and 170 unknown) from 19 countries were assessed. Gustatory impairment was the most common oral manifestation, with a prevalence of 45% (95% CI, 34% to 55%; I2 = 99%). The pooled eligible data for different taste disorders were 38% for dysgeusia and 35% for hypogeusia, while ageusia had a prevalence of 24%. Taste disorders were associated with COVID-19 (odds ratio [OR], 12.68; 95% CI, 6.41 to 25.10; I2 = 63%; P < 0.00001), mild/moderate severity (OR, 2.09; 95% CI, 1.25 to 3.49; I2 = 66%; P = 0.005), and female patients (OR, 1.64; 95% CI, 1.23 to 2.17; I2 = 70%; P = 0.0007). Oral mucosal lesions presented multiple clinical aspects, including white and erythematous plaques, irregular ulcers, small blisters, petechiae, and desquamative gingivitis. Tongue, palate, lips, gingiva, and buccal mucosa were affected. In mild cases, oral mucosal lesions developed before or at the same time as the initial respiratory symptoms; however, in those who required medication and hospitalization, the lesions developed approximately 7 to 24 d after onset symptoms. Therefore, taste disorders may be common symptoms in patients with COVID-19 and should be considered in the scope of the disease's onset and progression. Oral mucosal lesions are more likely to present as coinfections and secondary manifestations with multiple clinical aspects (PROSPERO CRD42020184468).

来源:J Dent Res,查看原文。版权归原作者所有。

引用

  1. Amorim Dos Santos J, Normando AGC, Carvalho da Silva RL, et al. Oral Manifestations in Patients with COVID-19: A Living Systematic Review. J Dent Res. 2020. PMID: 32914677. doi:10.1177/0022034520957289

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。